Contact

All Stories

  1. Patient-centered management of actinic keratosis. Results of a multi-center clinical consensus analyzing non-melanoma skin cancer patient profiles and field-treatment strategies

    Article • Journal of Dermatological Treatment, October 2019, Taylor & Francis

    Dr Lise Boussemart, ALESSANDRO DI STEFANI

  2. BRAF V600 mutations or fusions can be missed by some BRAF testing methods.

    Article • The Oncologist, January 2019, Alphamed Press

    Dr Lise Boussemart

  3. Melanoma tumour vasculature heterogeneity: from mice models to human

    Article • Journal of Cancer Research and Clinical Oncology, December 2018, Springer Science + Business Media

    Dr Lise Boussemart

  4. Desmoplatic melanomas carry many UV-induced mutations in their DNA.

    Article • Journal of the American Academy of Dermatology, December 2018, Elsevier

    Dr Lise Boussemart

  5. BRAF inhibitors do not only bind BRAFV600- proteins!

    Article • Nature Communications, November 2018, Springer Science + Business Media

    Dr Lise Boussemart

  6. Do the Side Effects of BRAF Inhibitors Mimic RASopathies?

    Article • Journal of Investigative Dermatology, April 2017, Elsevier

    Dr Lise Boussemart

  7. Woman, mother, and scientist: Aiming to fulfill a career in research while maintaining a “good-enough” work—life balance

    Article • International Journal of Women’s Dermatology, September 2016, Elsevier

    Dr Lise Boussemart

  8. Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization

    Article • Cancer Research, January 2016, American Association for Cancer Research (AACR)

    Dr Lise Boussemart

  9. The different types of personalities among academic vs private practice medical doctors, using PCM

    Article • MedEdPublish, January 2016, Association for Medical Education in Europe (AMEE)

    Dr Lise Boussemart

  10. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

    Article • JAMA Dermatology, January 2016, American Medical Association (AMA)

    Dr Lise Boussemart

  11. Abstract A23: eIF4F is a key and targetable convergence nexus of multiple mechanisms of resistance to anti-BRAF and anti-MEK cancer therapies

    Article • Clinical Cancer Research, February 2015, American Association for Cancer Research (AACR)

    Dr Lise Boussemart

  12. Abstract 934: BRAF inhibitors induce skin and extra-cutaneous tumors via paradoxical activation of the MAPK pathway: Molecular study of 66 tumors and visualization of BRAF/CRAF protein dimers

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Lise Boussemart

  13. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

    Article • Nature, July 2014, Nature

    Dr Lise Boussemart

  14. Traduction CAP-dépendante: une nouvelle cible thérapeutique dans le mélanome résistant au vemurafenib

    Article • Annales de Dermatologie et de Vénéréologie, December 2013, Elsevier

    Dr Lise Boussemart

  15. Tumeurs kératinocytaires induites par activation paradoxale de la voie MAPK sous inhibiteur de BRAF – Étude histologique, génétique, et virologique de 57 tumeurs secondaires

    Article • Annales de Dermatologie et de Vénéréologie, December 2013, Elsevier

    Dr Lise Boussemart

  16. Metastatic melanoma: New paradigms of treatment and new toxicities

    Article • European Journal of Cancer Supplements, September 2013, Elsevier

    Dr Lise Boussemart

  17. Vemurafenib and Radiosensitization

    Article • JAMA Dermatology, July 2013, American Medical Association (AMA)

    Dr Lise Boussemart

  18. Autoimmune Bullous Skin Diseases Occurring under Anti-Tumor Necrosis Factor Therapy: Two Case Reports

    Article • Dermatology, January 2010, Karger Publishers

    Dr Lise Boussemart

  19. BMP-4 is required for hepatic specification of mouse embryonic stem cell–derived definitive endoderm

    Article • Nature Biotechnology, November 2006, Nature

    Dr Lise Boussemart

  20. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus

    Article • Proceedings of the National Academy of Sciences, September 2004, Proceedings of the National Academy of Sciences

    Dr Lise Boussemart

  21. Polymorphism screening of PIK4CA: Possible candidate gene for chromosome 22q11-linked psychiatric disorders

    Article • American Journal of Medical Genetics, December 2002, Wiley

    Dr Lise Boussemart